Patents by Inventor Matthew Jonathan Jones

Matthew Jonathan Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
    Publication number: 20230151029
    Abstract: Disclosed herein are antimicrobial compounds, polymorphic forms, compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLIs). The boronic acid derivatives disclosed herein can be used in combination with various antibiotics to treat resistant bacteria.
    Type: Application
    Filed: March 17, 2021
    Publication date: May 18, 2023
    Inventors: Raja K. Reddy, David C. Griffith, Emily Rigsbee, Serge Henri Boyer, Scott J. Hecker, Matthew Jonathan Jones
  • Co-crystals of a triazolo [4,5-D] pyrimide platelet aggregation inhibitor
    Patent number: 8883802
    Abstract: The present invention relates to novel co-crystal forms of the compound of formula (I); wherein the co-former molecule is selected from glycolic acid, salicylic acid, decanoic (capric) acid, gentisic acid (2,5-dihydroxybenzoic acid), glutaric acid, vanillic acid (4-hydroxy-3-methoxybenzoic acid), succinic acid, malonic acid or maltol (3-hydroxy-2-methyl-4-pyrone); and to processes for their preparation, to pharmaceutical compositions containing such co-crystals, to the use of such co-crystals in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of a co-crystal of the compound of formula (I).
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: November 11, 2014
    Assignee: Astrazeneca AB
    Inventors: Stephen David Cosgrove, Matthew Jonathan Jones, Anna Polyakova-Akkus, Valeriya Nikolayevna Smolenskaya, Brenton Skylar Wolfe
  • Co-Crystals Of A Triazolo [4,5-D] Pyrimide Platelet Aggregation Inhibitor
    Publication number: 20130040970
    Abstract: The present invention relates to novel co-crystal forms of the compound of formula (I); wherein the co-former molecule is selected from glycolic acid, salicylic acid, decanoic (capric) acid, gentisic acid (2,5-dihydroxybenzoic acid), glutaric acid, vanillic acid (4-hydroxy-3-methoxybenzoic acid), succinic acid, malonic acid or maltol (3-hydroxy-2-methyl-4-pyrone); and to processes for their preparation, to pharmaceutical compositions containing such co-crystals, to the use of such co-crystals in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of a co-crystal of the compound of formula (I).
    Type: Application
    Filed: December 3, 2010
    Publication date: February 14, 2013
    Applicant: AstraZeneca AB
    Inventors: Stephen David Cosgrove, Matthew Jonathan Jones, Anna Polyakova-Akkus, Valeriya Nikolayevna Smolenskaya, Brenton Skylar Wolfe